Purple Biotech (PPBT) Assets Average (2014 - 2026)

Purple Biotech (PPBT) has 13 years of Assets Average data on file, last reported at $16.0 million in Q1 2026.

• Assets Average for Q1 2026 came in at $16.0 million, down 55.96% year-over-year; the trailing twelve-month figure through Mar 2026 was $16.0 million (down 55.96% YoY), and the FY2025 annual result was $27.3 million, down 32.86% from the prior year.
• Assets Average slipped to $16.0 million in Q1 2026 per PPBT's latest filing, from $28.3 million in the prior quarter.
• Over five years, Assets Average peaked at $68.2 million in Q1 2022 and troughed at $16.0 million in Q1 2026.
• A 5-year average of $44.0 million and a median of $42.1 million in 2024 frame the typical range for Assets Average.
• The sharpest annual moves came in 2025 and 2026: Assets Average rose 3.19% in 2025, then tumbled 55.96% in 2026.
• A 5-year view of Assets Average shows it stood at $56.6 million in 2022, then slipped by 20.85% to $44.8 million in 2023, then fell by 19.46% to $36.1 million in 2024, then dropped by 21.5% to $28.3 million in 2025, then plunged by 43.52% to $16.0 million in 2026.
• Business Quant data shows PPBT's Assets Average at $16.0 million in Q1 2026, $28.3 million in Q4 2025, and $36.7 million in Q3 2025.